We tested combinations of the EGFR/ERBB2 inhibitor neratinib with the cell cycle inhibitors (BI-2536, GSK-1070916 and paclitaxel or docetaxel) in the MYC-amplified cancer cell line NCI-H82. This evidence concerns the gene EGFR and cancer.